Request Demo
Last update 01 May 2026
DXC-006
Last update 01 May 2026
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms DXC 006, DXC-006 |
Target |
Action inhibitors |
Mechanism CD56 inhibitors(Neural cell adhesion molecule 1 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Related
3
Clinical Trials associated with DXC-006NCT06224855
An Open-label Dose Escalation and Cohort Expansion Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and and Efficacy of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
ChiCTR2400079372
An open-label dose escalation and cohort expansion phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and and efficacy of DXC006 in patients with advanced solid tumors and hematologic malignancies
CTR20261618
评估注射用DXC006联合免疫检查点抑制剂或铂类在小细胞肺癌研究参与者中的安全性和有效性的Ⅰb/Ⅱ期研究。
[Translation] A phase Ib/II study evaluating the safety and efficacy of injectable DXC006 in combination with immune checkpoint inhibitors or platinum-based drugs in participants of a small cell lung cancer study.
100 Clinical Results associated with DXC-006
Login to view more data
100 Translational Medicine associated with DXC-006
Login to view more data
100 Patents (Medical) associated with DXC-006
Login to view more data
100 Deals associated with DXC-006
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Small Cell Lung Cancer | Phase 2 | China | 30 Apr 2026 | |
| Multiple Myeloma | Phase 1 | China | 24 Jan 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 03 Jan 2024 | |
| Hematologic Neoplasms | Phase 1 | China | 03 Jan 2024 | |
| Neuroblastoma | Preclinical | China | 22 Mar 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free